<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04712201</url>
  </required_header>
  <id_info>
    <org_study_id>2017/09c</org_study_id>
    <nct_id>NCT04712201</nct_id>
  </id_info>
  <brief_title>En Bloc Bladder Tumor Resection: Prospective Randomized Study</brief_title>
  <official_title>En Bloc Bladder Tumor Resection: Prospective Randomized Evaluation of Monopolar, Bipolar and Laser Energy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacio Puigvert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KARL STORZ Endoscopy-America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacio Puigvert</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract.&#xD;
      Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors,&#xD;
      which are treatable through endourological procedures. The current standard is based on&#xD;
      conventional transurethral resection of bladder tumor, although high rates of recurrence have&#xD;
      been reported following resection of the primary tumor. Given the importance of a correct&#xD;
      initial diagnosis in these cases, en bloc transurethral resection has developed over the past&#xD;
      2 decades. This technique was born, according to the literature, with 3 main objectives: to&#xD;
      improve the quality of the surgical piece for its anatomopathological reading, reduce the&#xD;
      rate of postoperative complications and reduce the rate of relapses in the surgical bed. This&#xD;
      technique is used as a common practice of tumor resection in other centers and has been shown&#xD;
      in multiple publications that it does not increase surgical risk or negatively affect cancer&#xD;
      results.&#xD;
&#xD;
      OBJECTIVE The objective of our study is to compare feasibility, perioperative complication&#xD;
      rate, accuracy of staging and recurrence/progression rates when performing en bloc resection&#xD;
      by means of different energies: monopolar, bipolar and laser energy.&#xD;
&#xD;
      MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be&#xD;
      conducted including patients undergoing a transurethral resection of initial or recurrent&#xD;
      bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with&#xD;
      less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors&#xD;
      over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote&#xD;
      metastasis, whether lymphatic or organic, will be excluded.&#xD;
&#xD;
      Patients will be randomized into two groups:&#xD;
&#xD;
        -  Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according&#xD;
           to the energy used (monopolar, bipolar, laser energy).&#xD;
&#xD;
        -  Group 2 (control): Conventional transurethral resection (n-120). It will be divided into&#xD;
           2 subgroups depending on the energy used (monopolar or bipolar).&#xD;
&#xD;
      A fact sheet will be given to the patient about the study and the signature of the informed&#xD;
      consent will be requested in order to be included. The patient will be free to leave the&#xD;
      study at any time without having to provide any justification and without affecting the&#xD;
      treatment, intervention and follow-up that must be carried out.&#xD;
&#xD;
      The processing and storage of samples will be carried out in the pathological anatomy&#xD;
      laboratory, according to standard clinical practice.&#xD;
&#xD;
      Patients will be monitored according to the usual clinical practice protocol (minimum 5-year&#xD;
      follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert&#xD;
      Foundation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Staging of bladder tumor</measure>
    <time_frame>Three years</time_frame>
    <description>Evaluation of muscle presence in the specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative complications</measure>
    <time_frame>Three years</time_frame>
    <description>Bladder perforation grading, obturatory reflex, conversions to conventional TURB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of planned adjuvant treatment</measure>
    <time_frame>Three years</time_frame>
    <description>Rate of planned postoperative single instillation of mitomycin/epirubicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative complications</measure>
    <time_frame>Three years</time_frame>
    <description>Post-operative complications according to Clavien-Dindo System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substaging T1 bladder cancer</measure>
    <time_frame>Three years</time_frame>
    <description>T1a, T1b and T1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>Through study completion, an average of five years</time_frame>
    <description>Recurrence of bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Through study completion, an average of five years</time_frame>
    <description>Progression of bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Through study completion, an average of five years</time_frame>
    <description>Disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>Through study completion, an average of five years</time_frame>
    <description>Cancer specific survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Urothelial Carcinoma Bladder</condition>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>En bloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>En bloc transurethral resection of the bladder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional transurethral resection of the bladder</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>En bloc transurethral resection of bladder tumor (TURBT)</intervention_name>
    <description>En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy</description>
    <arm_group_label>En bloc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional TURBT</intervention_name>
    <description>Conventional transurethral resection of bladder tumor using monopolar and bipolar energy</description>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm&#xD;
&#xD;
          -  Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with&#xD;
             size less or equal than 3 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of &gt; 3 tumors or &gt; 3 cm&#xD;
&#xD;
          -  Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or&#xD;
             higher)&#xD;
&#xD;
          -  Computed tomography/magnetic resonance evidence of distant metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Gallioli, MD</last_name>
    <phone>0034934169730</phone>
    <email>agallioli@fundacio-puigvert.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacio Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gallioli, MD</last_name>
      <phone>0034934169730</phone>
      <email>agallioli@fundacio-puigvert.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacio Puigvert</investigator_affiliation>
    <investigator_full_name>Alberto Breda</investigator_full_name>
    <investigator_title>Chief of the Uro-Oncology Division and Kidney Transplant Unit</investigator_title>
  </responsible_party>
  <keyword>TURBT</keyword>
  <keyword>En bloc</keyword>
  <keyword>Urothelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

